


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently Amended) A compound of Formula (I):



or a salt or solvate thereof, wherein:

one of R^1 and R^2 is H and the other represents $-NHCONHR^4$,

wherein R^4 represents

a phenyl or naphthyl group $[(\text{I})]$ which may be optionally substituted by one or more substituents independently selected from $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, halogen, C_{1-6} alkoxy, C_{1-6} haloalkoxy, OH, $\text{NO}_2[(\text{I})]$, C_{3-7} cycloalkyl, indanyl, or

R^4 together with the NH to which it is bonded forms a morpholino group; and

R^3 is H or NHR^5

wherein R^5 is

H, -quinolinyl or -isoquinolinyl,

$-(\text{CONH})_p$ phenyl $[(\text{I})]$ wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from


halogen, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -morpholino, -SO₂NH₂, and methyl substituted benzothiazole (substituted by methyl).

~~or a salt, solvate, or physiologically functional derivative thereof.~~

2. (Currently Amended) A compound according to claim 1 wherein R⁴ represents C₃₋₇ cycloalkyl, indanyl, or a phenyl group ~~(which wherein said phenyl may be optionally substituted by one or more substituents selected from -C₁₋₆ haloalkyl, -CH₂CH₂CH₂-, and halogen) or C₃₋₇ cycloalkyl.~~

3. (Currently Amended) A compound according to claim[[s]] 1 [[- 2]] wherein R³ is H or -NH R⁵ wherein R⁵ is H, quinolinyl, or -(CONH)_p phenyl [[(]]wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C₁₋₆ haloalkyl -morpholino, -SO₂NH₂, and methyl substituted benzothiazole, ~~(substituted by methyl).~~

4. (Currently Amended) A compound according to claim[[s]] 1 [[- 3]] of formula (1a)




wherein one of R⁶ and R⁷ is H and the other represents -NHCONHR⁹;

R^9 represents C_{3-7} cycloalkyl, indanyl, or a phenyl group ~~(which wherein~~
said phenyl may be optionally substituted by one or more substituents
 independently selected from $-C_{1-6}$ haloalkyl, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, and halogen)~~or~~
 ~~C_{3-7} cycloalkyl;~~


R^8 is H or NHR^{10} ;


R^{10} is H, quinoliny, or $-(\text{CONH})_p$ phenyl ~~[[()]]~~ where p is 0 or 1 and the phenyl
 is optionally substituted by one or more substituents independently selected
 from halogen, $-C_{1-6}$ haloalkyl, -morpholino, $-\text{SO}_2\text{NH}_2$, and methyl substituted
 benzothiazole ~~(substituted by methyl))~~.

5. (Currently Amended) A compound according to claim 4 wherein
 NHCONHR^9 represents



6. (Currently Amended) A compound according to claim 4 ~~[[and 5]]~~
 where in R^{10} is H,





7. (Currently Amended) A compound as claimed in claim 1 [[- 6,]] selected from the group consisting of:

1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(3-isoquinolin-5-ylphenyl)urea;
 1-Cyclohexyl-3-(3-isoquinolin-5-ylphenyl)urea;
 1-[3-(1-Amino-isoquinolin-5-yl)-phenyl]-3-(2-fluoro-5-trifluoromethyl-phenyl)-urea ;
 1-(2-fluoro-5-trifluoromethyl-phenyl)-3-(5-{3-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-isoquinolin-1-yl)-urea;
 1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-{3-[1-(quinolin-6-ylamino)-isoquinolin-5-yl]-phenyl}-urea;
 1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(4-{1-[4-(6-methyl-benzothiazol-2-yl)-phenylamino]-isoquinolin-5-yl}-phenyl)-urea;
 1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(3-{1-[4-(6-methyl-benzothiazol-2-yl)-phenylamino]-isoquinolin-5-yl}-phenyl)-urea;
 1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(4-isoquinolin-5-ylphenyl)urea;
 1-Indan-5-yl-3-(3-isoquinolin-5-ylphenyl)-urea;
 1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-{3-[1-(4-morpholin-4-yl-phenylamino)-isoquinolin-5-yl]-phenyl}-urea; and
 3-{5-[3-(3-Cyclohexyl-ureido)-phenyl]-isoquinolin-1-ylamino}-benzenesulfonamide;

or a salt[[,]] or solvate, ~~or physiologically functional derivative~~ thereof.

8. (Currently Amended) A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim[[s]] 1 [[- 7]], or a salt[[,]] or solvate, ~~or a physiologically functional~~

~~derivative~~ thereof and one or more of pharmaceutically acceptable carriers, diluents, and excipients.

9. (Original) A pharmaceutical composition according to claim 8 further comprising an agent to inhibit growth factor receptor function

10. (Cancelled)

11. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2, Eph B4, and VEGFR-2 activity, comprising administering to said mammal a compound according to claim[[s]] 1 [[- 7]] or a salt[[,]] or solvate ~~or a physiologically functional derivative~~ thereof.

12. (Cancelled)

13. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2, Eph B4, and VEGFR-2 activity, comprising: administering to said mammal (i) a compound according to claim[[s]] 1 [[- 7]], or a salt[[,]] or solvate ~~or physiologically functional derivative~~ thereof and (ii) an agent to inhibit growth factor receptor function.

14. (Cancelled)

15. (Currently Amended) A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, comprising administering to said mammal a compound according to claim[[s]] 1 [[- 7]], or a salt[[,]] or solvate ~~or physiologically functional derivative~~ thereof.

16. (Cancelled)